Published by Dr. Tanner Hewitt, Dr. Larry Wang and Dr. Bradley Miller
Health & Fitness
Medicine
Welcome to Psych Rounds, the podcast tailored for psychiatry residents and students. Join us, three psychiatric resident physicians, as we delve into quick insights, interviews, and practical tips essential for educational practice. Subscribe for a straightforward yet informal approach to psychiatric knowledge. Contact us: psychroundspodcast@gmail.com Instagram: https://www.instagram.com/psychrounds/
Today we're starting a new type of series - looking at some of the most seminal studies in psychiatry. We're going to start with the CATIE Trial, which was published in 2005. References: https://www.nejm.org/doi/full/10.1056/NEJMoa051688 https://pubmed.ncbi.nlm.nih.gov/19594194/ https://pubmed.ncbi.nlm.nih.gov/17924259/ https://pubmed.ncbi.nlm.nih.gov/17286522/ https://www.nejm.org/doi/full/10.1056/NEJMoa061240 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/209844
Apologies for our little hiatus - a couple of us had cross-country moves in June. But we're back! Today we have an episode on the rising use of recreational Kratom and pertinent tidbits to know from a psychiatry standpoint. References: https://pmc.ncbi.nlm.nih.gov/articles/PMC8924421/ https://www.ncbi.nlm.nih.gov/books/NBK585120/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10846393/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10177737/
Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry. References: Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda docs/label/2015/020717s037s038lbl.pdf Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85. Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642 Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4 Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560 Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119 Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859
Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry. References: https://www.ncbi.nlm.nih.gov/books/NBK534811/ https://pubmed.ncbi.nlm.nih.gov/24825644/ https://pubmed.ncbi.nlm.nih.gov/26798982/ https://www.nejm.org/doi/full/10.1056/NEJMct0801733 https://pubmed.ncbi.nlm.nih.gov/26798982/
Welcome back! Today, we will be discussing the placebo effect. References: https://pubmed.ncbi.nlm.nih.gov/16503356/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003660/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556377/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714297/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178 / https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/2018/11/19/understanding-placebo
Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). References: https://pubmed.ncbi.nlm.nih.gov/41626799/ https://www.ncbi.nlm.nih.gov/books/NBK548187/ https://pubmed.ncbi.nlm.nih.gov/41626799/
We are back with another special guest episode! Please welcome Dr. Allen Frances, who was intricately involved in the formation of both the DSM III and DSM IV, the latter of which he served as chair. https://x.com/AllenFrancesMD https://www.amazon.com/stores/author/B001HO76FU https://www.psychiatrictimes.com/authors/allen-frances-md
Welcome back! Today we will be doing a brief episode on Topiramate [Topamax], and its clinical uses in psychiatry. References : https://pubmed.ncbi.nlm.nih.gov/21438989/ https://pubmed.ncbi.nlm.nih.gov/18774432/ https://pubmed.ncbi.nlm.nih.gov/25899459/ https://pmc.ncbi.nlm.nih.gov/articles/PMC1088011/ https://pmc.ncbi.nlm.nih.gov/articles/PMC2671954/ https://pubmed.ncbi.nlm.nih.gov/38706338/ https://pubmed.ncbi.nlm.nih.gov/20207521/
Welcome back, today we are discussing a deceptively difficult topic: What makes something a psychiatric illness? We are joined by our guest Dr. Mark Ruffalo. He is a psychotherapist in private practice in Tampa, FL, and who also serves as Assistant Professor of Psychiatry at the University of Central Florida College of Medicine as well an Adjunct Assistant Professor of Psychiatry at Tufts University School of Medicine. Dr. Ruffalo's Website: https://www.drruffalo.com/ Dr. Ruffalo's LinkedIn: https://www.linkedin.com/in/mark-l-ruffalo-71929063 PRISM: https://www.psychiatrictimes.com/view/use-of-the-prism-diagnostic-instrument-in-clinical-practice PRISM Writing Contest: https://www.psychiatrictimes.com/view/prism-writing-contest-more-on-this-new-diagnostic-tool-from-mark-ruffalo-msw-dpsa
Welcome back! Today we are at the highly prescribed and popular benzodiazepine Lorazepam, also known as Ativan. We look at its uses in psychiatry, especially catatonia. But despite anecdotal efficacy, does the evidence hold up? References: https://www.ncbi.nlm.nih.gov/books/NBK532890/ https://pubmed.ncbi.nlm.nih.gov/36805317/ https://pubmed.ncbi.nlm.nih.gov/6120058/ https://pubmed.ncbi.nlm.nih.gov/10229064/ https://psychopharmacologyinstitute.com/section/catatonia-diagnosis-the-lorazepam-challenge-2911-5899/
Welcome back! Today we are embarking into the first of hopefully several episodes on the importance of vitamins and minerals in mental health. We will specifically be looking at the role of iron deficiency in psychiatry and do an overview on some of the recent research that's been published. References: https://www.ncbi.nlm.nih.gov/books/NBK557376/ https://www.sciencedirect.com/science/article/pii/S0268960X25000827#bb0165 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823909 https://www.sciencedirect.com/science/article/pii/S1389945717315599 https://pubmed.ncbi.nlm.nih.gov/40841680/ https://pubmed.ncbi.nlm.nih.gov/1677067/ https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00463-7/fulltext https://pmc.ncbi.nlm.nih.gov/articles/PMC6139360/
Welcome back! Today our topic is Nutritional Psychiatry and we've invited a special guest - Dr. Laura Lachance, who has done extensive research in the field. Along with Dr. Drew Ramsey, she has published a paper looking at an Antidepressant Food Score or AFS and more recently, she was a part of the EASe-GAD trial, a study looking at the impact of omega-3 fatty acids on anxiety. Antidepressant Food Scale (AFS): https://pubmed.ncbi.nlm.nih.gov/30254980/ EASe-GAD Trial: https://pubmed.ncbi.nlm.nih.gov/39316026/ Gluten and Psychosis: https://pubmed.ncbi.nlm.nih.gov/24368154/ Nutrition Worksheet for Patients: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-021-03575-7 Dr. Lachance's Instagram: https://www.instagram.com/preventivepsychiatry/
Welcome back! Today, we are hosting the highly accomplished Dr. Robert Sapolsky, PHD, a professor of professor of biology, neurology, and neurosurgery at Stanford University. He has had extensive research particularly in the field of neuroendocrinology and chronic stress, which has acted as one of the foundations of modern psychoneuroendocrinology. He is also a research associate at the Institute of Primate Research in Kenya, with over 30 years of field research in Africa. He is also a renowned author, with major works including but not at all limited to Why Zebras Don’t Get Ulcers , Behave: The Biology of Humans at Our Best and Worst , and most recently, Determined: A Science of Life Without Free Will , which challenges us to reconsider free will, morality, and mental health itself through a scientific lens. More about Dr. Sapolsky: https://en.wikipedia.org/wiki/Robert_Sapolsky Dr. Sapolsky's Open Stanford Course: https://www.youtube.com/watch?v=-PpDq1WUtAw&list=PL848F2368C90DDC3D Dr. Sapolsky's Books: https://www.amazon.com/stores/author/B000APOCFE Dr. Sapolsky's Own Podcast: Spotify: https://open.spotify.com/show/0wDrkkznSB8S84kKuK9HCo Apple: https://podcasts.apple.com/us/podcast/robert-sapolsky-father-offspring-interviews/id1782280922
One hundred episodes later, let’s take it back to one of our very first, the Selective Serotonin Reuptake Inhibitors - with a much-needed update. Thank you to our guests, fans, and listeners. References: https://pmc.ncbi.nlm.nih.gov/articles/PMC4428540/ https://pubmed.ncbi.nlm.nih.gov/10333979 https://pmc.ncbi.nlm.nih.gov/articles/PMC3663330/
Welcome back! Today we have a very special episode on Alprazolam, brand-name Xanax. This benzodiazepine is one of the most commonly-prescribed and sought out psychotropic medications. https://www.ncbi.nlm.nih.gov/books/NBK538165/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6769182/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5846112/ https://pubmed.ncbi.nlm.nih.gov/6141930/ https://pubmed.ncbi.nlm.nih.gov/17514187/
Join us today for an episode on the impact of climate change on mental health. We'll be exploring concepts like eco-anxiety, advocacy, the impact of nuclear war and practical tips. We're joined by guest Dr. Ferdnand Osuagwu, who was the former Chair of the Caucus on Climate Change and Mental Health of the American Psychiatric Association (APA) and founder of the Ferdnand Foundation International, an organization dedicated to underserved and marginalized populations and with a particular emphasis on addressing their needs in the areas of health, education, climate change, social justice and resource mobilization. Ferdnand Foundation Website: https://ferdnandfoundation.org/ Ferdnand Foundation Youtube Channel: https://www.youtube.com/@FerdnandFoundation/featured
Today, we are talking about a very popular, yet controversial class of medications - the Benzodiazepines . Let's look at their mechanism of action, clinical indications, pharmacology, risks, withdrawal syndromes, and prescribing guidance. And of course, we'll be tackling the question: what are the risks and benefits of long-term use? References: https://pubmed.ncbi.nlm.nih.gov/30098211/ https://pubmed.ncbi.nlm.nih.gov/32252539/ https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates https://aapp.org/guideline/benzo https://pubmed.ncbi.nlm.nih.gov/40526204/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/ https://www.ncbi.nlm.nih.gov/books/NBK470159/ https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment/article/benzodiazepines-for-anxiety-disorders-maximising-the-benefits-and-minimising-the-risks/43A366723CD1B3616BAB08F69FF65A88
Welcome to an introductory episode on anxiety disorders as requested by a long-time listener. References: https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5573565/ https://deepblue.lib.umich.edu/bitstream/handle/2027.42/175862/Nesse%20Anxiety%20Disorders%20in%20Evolutionary%20Perspective%202022.pdf?sequence=1
Join us as we talk about Loxapine, an older medication that’s stood the test of time and found a niche in psychiatric practice. This is a revision of an earlier episode, after Dr. Bradley Miller chatted with Dr. Jonathan Meyer at the 2025 APA Conference. Dr. Meyer joins us at the beginning to provide an addendum to the original episode.
